Ravoxertinib
| CAS No. | 1453848-26-4 | Cat. No. | BCP09668 |
| Name | Ravoxertinib | ||
| Synonyms | GDC0994; GDC-0994; GDC 0994; RG7842; RG-7842; RG 7842;; | ||
| Formula | C21H18ClFN6O2 | M. Wt | 440.86 |
| Description | Ravoxertinib also known as GDC-0994 and RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. | ||
| Pathways | MAPK Pathway | ||
| Targets | MEK/ERK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.